US2002010949A1PendingUtilityA1

Cloning using donor nuclei from differentiated fetal and adult cells

46
Assignee: UNIV MASSACHUSETTS AMHERST CAMPriority: Jan 10, 1997Filed: Apr 10, 2001Published: Jan 24, 2002
Est. expiryJan 10, 2017(expired)· nominal 20-yr term from priority
A61P 31/18A61P 3/10A61P 9/04A61P 35/00A61P 9/00A61P 25/28A61P 25/16A61K 35/12A61P 1/18C12N 2517/04C12N 2517/02C12N 5/0603A01K 67/0275C12N 15/8778A01K 2227/106A01K 2227/101C12N 15/8771A01K 2217/05A61P 13/02A61P 21/00A61P 17/02A01K 67/027C12N 2510/00
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An improved method of nuclear transfer involving the transplantation of donor differentiated cell nuclei into enucleated oocytes of the same species as the donor cell is provided. The resultant nuclear transfer units are useful for multiplication of genotypes and transgenic genotypes by the production of fetuses and offspring, and for production of isogenic CICM cells, including human isogenic embryonic or stem cells. Production of genetically engineered or transgenic mammalian embryos, fetuses and offspring is facilitated by the present method since the differentiated cell source of the donor nuclei can be genetically modified and clonally propagated.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of cloning a mammal, comprising: 
 (i) inserting a desired differentiated mammalian cell or cell nucleus into an enucleated mammalian oocyte of the same species as the differentiated cell or cell nucleus, under conditions suitable for the formation of a nuclear transfer (NT) unit;    (ii) activating the resultant nuclear transfer unit;    (iii) culturing said activated nuclear transfer unit until greater than the 2-cell developmental stage; and    (iv) transferring said cultured NT unit to a host mammal such that the NT unit develops into a fetus.    
     
     
         2 . The method according to  claim 1 , which further comprises developing the fetus to an offspring.  
     
     
         3 . The method according to  claim 1 , wherein a desired DNA is inserted, removed or modified in said differentiated mammalian cell or cell nucleus, thereby resulting in the production of a genetically altered NT unit.  
     
     
         4 . The method according to  claim 3 , which further comprises developing the fetus to an offspring.  
     
     
         5 . The method according to  claim 1 , wherein the differentiated mammalian cell or cell nucleus is derived from mesoderm.  
     
     
         6 . The method according to  claim 1 , wherein the differentiated mammalian cell or cell nucleus is derived from ectoderm.  
     
     
         7 . The method according to  claim 1 , wherein the differentiated mammalian cell or cell nucleus is derived from endoderm.  
     
     
         8 . The method according to  claim 1 , wherein the differentiated mammalian cell or cell nucleus is a fibroblast cell or cell nucleus.  
     
     
         9 . The method according to  claim 1 , wherein the differentiated mammalian cell or cell nucleus is from an ungulate.  
     
     
         10 . The method according to  claim 9 , wherein the ungulate is selected from the group consisting of bovine, ovine, porcine, equine, caprine and buffalo.  
     
     
         11 . The method according to  claim 1 , wherein the differentiated mammalian cell or cell nucleus is an adult cell or cell nucleus.  
     
     
         12 . The method according to  claim 1 , wherein the differentiated mammalian cell or cell nucleus is an embryonic or fetal cell or cell nucleus.  
     
     
         13 . The method according to  claim 1 , wherein the enucleated oocyte is matured prior to enucleation.  
     
     
         14 . The method according to  claim 1 , wherein the fused nuclear transfer unit is activated by exposure to ionomycin and 6-dimethylaminopurine.  
     
     
         15 . The method according to  claim 3 , wherein microinjection is used to insert a heterologous DNA.  
     
     
         16 . The method according to  claim 3 , wherein electroporation is used to insert a heterologous DNA.  
     
     
         17 . A fetus obtained according to the method of  claim 1 .  
     
     
         18 . An offspring obtained according to the method of  claim 2 .  
     
     
         19 . Progeny of the offspring according to  claim 18 .  
     
     
         20 . A transgenic fetus obtained according to the method of  claim 3 .  
     
     
         21 . A transgenic offspring obtained according to the method of  claim 4 .  
     
     
         22 . Progeny of the offspring according to  claim 21 .  
     
     
         23 . The method according to  claim 1 , which further comprises combining the cloned NT unit with a fertilized embryo to produce a chimeric embryo.  
     
     
         24 . The method according to  claim 23 , which further comprises developing the fetus to an offspring.  
     
     
         25 . A fetus obtained according to the method of  claim 23 .  
     
     
         26 . An offspring obtained according to the method of  claim 24 .  
     
     
         27 . Progeny of the mammal according to  claim 26 .  
     
     
         28 . A method of producing a CICM cell line, comprising: 
 (i) inserting a desired differentiated mammalian cell or cell nucleus into an enucleated mammalian oocyte of the same species as the differentiated cell or cell nucleus, under conditions suitable for the formation of a nuclear transfer (NT) unit;    (ii) activating the resultant nuclear transfer unit;    (iii) culturing said activated nuclear transfer unit until greater than the 2-cell developmental stage; and    (iv) culturing cells obtained from said cultured NT unit to obtain a CICM cell line.    
     
     
         29 . A CICM cell line obtained according to the method of  claim 28 .  
     
     
         30 . The method according to  claim 28 , wherein a desired DNA is inserted, removed or modified in said differentiated mammalian cell or cell nucleus, thereby resulting in the production of a genetically altered NT unit.  
     
     
         31 . A transgenic CICM cell line obtained according to  claim 30 .  
     
     
         32 . The method of  claim 28 , wherein the resultant CICM cell line is induced to differentiate.  
     
     
         33 . Differentiated cells obtained by the method of  claim 32 .  
     
     
         34 . Human differentiated cells obtained by the method of  claim 32 .  
     
     
         35 . A method of therapy which comprises administering to a patient in need of cell transplantation therapy isogenic differentiated cells according to  claim 34 .  
     
     
         36 . The method of  claim 35 , wherein said cell transplantation therapy is effected to treat a disease or condition selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's disease, ALS, spinal cord defects or injuries, multiple sclerosis, muscular dystrophy, cystic fibrosis, liver disease, diabetes, heart disease, cartilage defects or injuries, bums, foot ulcers, vascular disease, urinary tract disease, AIDS and cancer.  
     
     
         37 . A method of therapy which comprises administering to a human patient in need of cell transplantation therapy xenogenic differentiated cells according to  claim 33 .  
     
     
         38 . The method according to  claim 37  wherein the xenogenic differentiated cells are bovine cells.  
     
     
         39 . The method of  claim 37 , wherein said cell transplantation therapy is effected to treat a disease or condition selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's disease, ALS, spinal cord defects or injuries, multiple sclerosis, muscular dystrophy, cystic fibrosis, liver disease, diabetes, heart disease, cartilage defects or injuries, burns, foot ulcers, vascular disease, urinary tract disease, AIDS and cancer.  
     
     
         40 . The method of  claim 35 , wherein the differentiated human cells are hematopoietic cells or neural cells.  
     
     
         41 . The method of  claim 35 , wherein the therapy is for treatment of Parkinson's disease and the differentiated cells are neural cells.  
     
     
         42 . The method of  claim 35 , wherein the therapy is for the treatment of cancer and the differentiated cells are hematopoietic cells.  
     
     
         43 . A method of therapy which comprises administering to a human patient in need of cell transplantation therapy xenogenic cells obtained from a fetus according to  claim 17 .  
     
     
         44 . The method according to  claim 43  wherein the xenogenic cells are bovine cells.  
     
     
         45 . The method of  claim 43 , wherein said cell transplantation therapy is effected to treat a disease or condition selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's disease, ALS, spinal cord defects or injuries, multiple sclerosis, muscular dystrophy, cystic fibrosis, liver disease, diabetes, heart disease, cartilage defects or injuries, bums, foot ulcers, vascular disease, urinary tract disease, AIDS and cancer.  
     
     
         46 . A method of therapy which comprises administering to a human patient in need of cell transplantation therapy xenogenic cells obtained from an offspring according to  claim 18 .  
     
     
         47 . The method according to  claim 46  wherein the xenogenic cells are bovine cells.  
     
     
         48 . The method of  claim 46 , wherein said cell transplantation therapy is effected to treat a disease or condition selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's disease, ALS, spinal cord defects or injuries, multiple sclerosis, muscular dystrophy, cystic fibrosis, liver disease, diabetes, heart disease, cartilage defects or injuries, burns, foot ulcers, vascular disease, urinary tract disease, AIDS and cancer.  
     
     
         49 . A method of therapy which comprises administering to a human patient in need of cell transplantation therapy xenogenic transgenic cells obtained from a transgenic fetus according to  claim 20 .  
     
     
         50 . The method according to  claim 49  wherein the xenogenic transgenic cells are bovine cells.  
     
     
         51 . The method of  claim 49 , wherein said cell transplantation therapy is effected to treat a disease or condition selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's disease, ALS, spinal cord defects or injuries, multiple sclerosis, muscular dystrophy, cystic fibrosis, liver disease, diabetes, heart disease, cartilage defects or injuries, bums, foot ulcers, vascular disease, urinary tract disease, AIDS and cancer.  
     
     
         52 . A method of therapy which comprises administering to a human patient in need of cell transplantation therapy xenogenic transgenic cells obtained from a transgenic offspring according to  claim 21 .  
     
     
         53 . The method according to  claim 52  wherein the xenogenic transgenic cells are bovine cells.  
     
     
         54 . The method of  claim 52 , wherein said cell transplantation therapy is effected to treat a disease or condition selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's disease, ALS, spinal cord defects or injuries, multiple sclerosis, muscular dystrophy, cystic fibrosis, liver disease, diabetes, heart disease, cartilage defects or injuries, bums, foot ulcers, vascular disease, urinary tract disease, AIDS and cancer.  
     
     
         55 . The method according to  claim 28 , which further comprises combining the cloned NT unit with a fertilized embryo to produce a chimera.  
     
     
         56 . The method according to  claim 55 , which further comprises developing the chimeric CICM cell line to a chimeric embryo.  
     
     
         57 . A chimeric embryo obtained according to  claim 56 .  
     
     
         58 . The method according to  claim 56 , which further comprises developing the chimeric embryo to a chimeric fetus.  
     
     
         59 . A chimeric fetus obtained according to  claim 58 .  
     
     
         60 . The method according to  claim 58 , which further comprises developing the chimeric fetus to a chimeric offspring.  
     
     
         61 . A chimeric offspring obtained according to  claim 60 .  
     
     
         62 . The method according to  claim 55 , wherein a desired DNA is inserted, removed or modified in said differentiated mammalian cell or cell nucleus, thereby resulting in the production of a genetically altered NT unit.  
     
     
         63 . The method according to  claim 62 , which further comprises developing the chimeric CICM cell line to a chimeric embryo.  
     
     
         64 . A chimeric embryo obtained according to  claim 63 .  
     
     
         65 . The method according to  claim 63 , which further comprises developing the chimeric embryo to a chimeric fetus.  
     
     
         66 . A chimeric fetus obtained according to  claim 65 .  
     
     
         67 . The method according to  claim 65 , which further comprises developing the chimeric fetus to a chimeric offspring.  
     
     
         68 . A chimeric offspring obtained according to  claim 67 .  
     
     
         69 . A method of cloning a mammal, comprising: 
 (i) inserting a desired differentiated CICM cell or cell nucleus into an enucleated mammalian oocyte of the same species as the differentiated CICM cell or cell nucleus, under conditions suitable for the formation of a nuclear transfer (NT) unit;    (ii) activating the resultant nuclear transfer unit;    (iii) culturing said activated nuclear transfer unit until greater than the 2-cell developmental stage; and    (iv) transferring said cultured NT unit to a host mammal such that the NT unit develops into a fetus.    
     
     
         70 . The method according to  claim 69 , which further comprises developing the fetus to an offspring.  
     
     
         71 . A fetus obtained according to the method of  claim 69 .  
     
     
         72 . An offspring obtained according to the method of  claim 70 .  
     
     
         73 . An organ for use as an organ xenograft, which is obtained from the offspring according to  claim 18 .  
     
     
         74 . An organ for use as an organ xenograft, which is obtained from the offspring according to  claim 21 .  
     
     
         75 . An organ for use as an organ xenograft, which is obtained from the offspring according to  claim 26 .  
     
     
         76 . An organ for use as an organ xenograft, which is obtained from the offspring according to  claim 68 .  
     
     
         77 . An organ for use as an organ xenograft, which is obtained from the offspring according to claim  72 .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.